Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
Susanna B. Park,David Goldstein,Arun V. Krishnan,Cindy S.-Y. Lin,Michael Friedlander,James T. Cassidy,Martin Koltzenburg,Matthew C. Kiernan +7 more
Reads0
Chats0
TLDR
This review will address the increasing importance and challenge of chemotherapy‐induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers.Abstract:
With a 3-fold increase in the number of cancer survivors noted since the 1970s, there are now over 28 million cancer survivors worldwide. Accordingly, there is a heightened awareness of long-term toxicities and the impact on quality of life following treatment in cancer survivors. This review will address the increasing importance and challenge of chemotherapy-induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers. An overview of the diagnosis, symptomatology, and pathophysiology of chemotherapy-induced peripheral neuropathy will be provided, with a critical analysis of assessment strategies, neuroprotective approaches, and potential treatments. The review will concentrate on neuropathy associated with taxanes, platinum compounds, vinca alkaloids, thalidomide, and bortezomib, providing clinical information specific to these chemotherapies. CA Cancer J Clin 2013;63:419-437. ©2013 American Cancer Society, Inc.read more
Citations
More filters
Journal ArticleDOI
Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT).
Bengt Glimelius,Nebojsa Manojlovic,Per Pfeiffer,Baadur Mosidze,Galina Kurteva,Mia Karlberg,Devalingam Mahalingam,Peter Buhl Jensen,Jan Kowalski,Marie Helene Bengtson,Malin Nittve,Jacques Näsström +11 more
TL;DR: Calmangafodipir at a dose of 5 µmol/kg appears to prevent the development of oxaliplatin-induced acute and delayed CIPN without apparent influence on tumour outcomes.
Journal ArticleDOI
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.
Heinz Ludwig,Michel Delforge,Thierry Facon,Hermann Einsele,Philippe Moreau,Hervé Avet-Loiseau,Mario Boccadoro,Roman Hájek,Mohamad Mohty,Michele Cavo,Meletios A. Dimopoulos,Jesús F. San-Miguel,Evangelos Terpos,Sonja Zweegman,Laurent Garderet,Maria-Victoria Mateos,Gordon Cook,Xavier Leleu,Hartmut Goldschmidt,Graham Jackson,Martin Kaiser,Katja Weisel,Niels W.C.J. van de Donk,Anders Waage,Meral Beksac,Ulf H. Mellqvist,Monika Engelhardt,Jo Caers,Christoph Driessen,Joan Bladé,Pieter Sonneveld +30 more
TL;DR: In this review, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome and present with very specific side effect profiles.
Journal ArticleDOI
ReCAP: ASCO Core Curriculum for Cancer Survivorship Education.
Charles L. Shapiro,Paul B. Jacobsen,Tara O. Henderson,Arti Hurria,Larissa Nekhlyudov,Andrea K. Ng,Antonella Surbone,Deborah K. Mayer,Julia H. Rowland +8 more
TL;DR: Fundamental to the relatively new field of survivorship care is this core curriculum and competencies, which provide the framework necessary to generate appropriate referrals depending on local practices and expertise.
Journal ArticleDOI
Bortezomib-induced peripheral neurotoxicity: an update.
Andreas A. Argyriou,Guido Cavaletti,Jordi Bruna,Athanasios P. Kyritsis,Haralabos P. Kalofonos +4 more
TL;DR: A critical exploration of updates concerning the spectrum of characteristics and treatment options of bortezomib-induced peripheral neuropathy (BIPN) is provided, with emphasis on pathogenesis issues.
Journal ArticleDOI
From the Bottom-Up: Chemotherapy and Gut-Brain Axis Dysregulation.
TL;DR: It is hypothesized that dysregulation of the gut-brain axis plays a major role in the intestinal, psychological and neurological complications following chemotherapy, with particular attention to evidence surrounding microbiota dysbiosis.
References
More filters
Journal ArticleDOI
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
A. de Gramont,A. Figer,M. Seymour,M. Homerin,A. Hmissi,J. Cassidy,Corrado Boni,H. Cortes-Funes,Andrés Cervantes,Gilles Freyer,Demetris Papamichael,N. Le Bail,C. Louvet,D. Hendler,F. de Braud,C. Wilson,Francois Morvan,Andrea Bonetti +17 more
TL;DR: The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
Journal ArticleDOI
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Thierry André,Corrado Boni,Lamia Mounedji-Boudiaf,Matilde Navarro,Josep Tabernero,Tamas Hickish,C. Topham,Marta Zaninelli,Phillip Clingan,John Bridgewater,Isabelle Tabah-Fisch,Aimery de Gramont +11 more
TL;DR: Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
Journal ArticleDOI
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
Andy Trotti,A. Dimitrios Colevas,Ann Setser,Valerie W. Rusch,David P. Jaques,Volker Budach,Corey J. Langer,Barbara A. Murphy,Richard Cumberlin,C. Norman Coleman,Philip Rubin +10 more
TL;DR: Recent progress in the evolution of adverse effects grading systems is updated and the development of CTCAE v3.0 is reviewed, which represents an international collaboration and consensus of the oncology research community.
Journal ArticleDOI
Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values
Roman Rolke,Ralf Baron,Christoph Maier,Thomas R. Tölle,Rolf-Detlef Treede,Antje Beyer,Andreas Binder,Niels Birbaumer,Frank Birklein,I. C. Bötefür,S. Braune,Herta Flor,Volker Huge,R. Klug,G. B. Landwehrmeyer,Walter Magerl,Christian Maihöfner,C. Rolko,C. Schaub,Andrea Scherens,Till Sprenger,Michael Valet,B. Wasserka +22 more
TL;DR: Application of this standardized QST protocol in patients and human surrogate models will allow to infer underlying mechanisms from somatosensory phenotypes as well as judge plus or minus signs in patients.
Related Papers (5)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman,Christina Lacchetti,Robert H. Dworkin,Ellen M. Lavoie Smith,Jonathan Bleeker,Guido Cavaletti,Cynthia Chauhan,Patrick Gavin,Antoinette Lavino,Maryam B. Lustberg,Judith A. Paice,Bryan P. Schneider,Mary Lou Smith,Thomas J. Smith,Shelby A. Terstriep,Nina D. Wagner-Johnston,Kate Bak,Charles L. Loprinzi +17 more